Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E13.73 EPS (ttm)8.02 Insider Own0.22% Shs Outstand708.21M Perf Week0.94%
Market Cap77.92B Forward P/E8.88 EPS next Y12.39 Insider Trans-0.74% Shs Float708.21M Perf Month8.96%
Income5.80B PEG0.93 EPS next Q2.82 Inst Own74.70% Short Float1.67% Perf Quarter16.13%
Sales16.98B P/S4.59 EPS this Y4.80% Inst Trans-0.68% Short Ratio3.22 Perf Half Y15.30%
Book/sh17.04 P/B6.46 EPS next Y11.17% ROA15.30% Target Price103.40 Perf Year56.63%
Cash/sh15.39 P/C7.15 EPS next 5Y14.70% ROE64.50% 52W Range58.59 - 110.70 Perf YTD71.66%
Dividend- P/FCF9.91 EPS past 5Y26.50% ROI16.50% 52W High-0.61% Beta1.40
Dividend %- Quick Ratio2.80 Sales past 5Y18.70% Gross Margin96.30% 52W Low87.78% ATR1.12
Employees8852 Current Ratio2.90 Sales Q/Q16.10% Oper. Margin46.50% RSI (14)78.95 Volatility0.97% 1.09%
OptionableYes Debt/Eq1.64 EPS Q/Q49.20% Profit Margin34.60% Rel Volume1.13 Prev Close110.41
ShortableYes LT Debt/Eq1.51 EarningsOct 31 BMO Payout0.00% Avg Volume3.67M Price110.02
Recom3.00 SMA203.04% SMA507.78% SMA20015.71% Volume4,150,528 Change-0.35%
Nov-01-19Downgrade Standpoint Research Buy → Hold
Nov-01-19Downgrade Robert W. Baird Outperform → Neutral $101
Aug-19-19Downgrade Mizuho Buy → Neutral $103 → $100
May-03-19Downgrade Barclays Overweight → Equal Weight $102
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Nov-15-19 02:00AM  US regulator issues first approval for a Chinese cancer treatment Financial Times
Nov-14-19 10:36AM  Top Ranked Growth Stocks to Buy for November 14th Zacks
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks
10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
08:00AM  BMY Stock Plus Celgene Will Be A Top 5 Pharma But Should You Buy It? Investor's Business Daily
Nov-12-19 03:24PM  How KKR Could Pull Off a Walgreens Takeover Barrons.com
09:14AM  Top Ranked Growth Stocks to Buy for November 12th Zacks
09:00AM  Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing CNW Group
08:18AM  The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene Zacks
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
09:15AM  Celgene (CELG) Hits 52-Week High, Can the Run Continue? Zacks
09:05AM  Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug Zacks
Nov-08-19 04:25PM  How Celgene Added A New Drug To Its Wheelhouse A Month Early Investor's Business Daily
02:24PM  Celgene's rare disease drug gets FDA approval MarketWatch
02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
12:55PM  UPDATE 2-Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial Reuters
12:33PM  FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Business Wire
10:31AM  Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales Zacks
Nov-07-19 01:06PM  P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook Moody's
Nov-06-19 03:14PM  Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3 Zacks
11:29AM  Top Ranked Momentum Stocks to Buy for November 6th Zacks
10:20AM  Will Celgene (CELG) Gain on Rising Earnings Estimates? Zacks
10:00AM  Celgene (CELG) Is Up 3.16% in One Week: What You Should Know Zacks
09:30AM  Is Celgene (CELG) Outperforming Other Medical Stocks This Year? Zacks
09:30AM  CELG vs. TECH: Which Stock Is the Better Value Option? Zacks
09:06AM  Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting Business Wire
08:45AM  3 Reasons Why Celgene (CELG) Is a Great Growth Stock Zacks
Nov-05-19 01:56PM  The Biggest Biotech Just Touched A Record High Is Amgen Stock A Buy? Investor's Business Daily
10:15AM  The Zacks Analyst Blog Highlights: Facebook, JPMorgan Chase, Royal Dutch Shell, Starbucks and Celgene Zacks
10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
08:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-04-19 05:05PM  Biotech ETFs in Focus on Impressive Q3 Earnings Results Zacks
03:05PM  Top Stock Reports for Facebook, JPMorgan & Royal Dutch Shell Zacks
01:00PM  Value Biotech ETFs & Stocks to Buy Now Zacks
11:54AM  ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally Zacks
Nov-01-19 12:07PM  Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
11:33AM  2 Health Stocks With Gains Thursday GuruFocus.com
11:18AM  Two Trending healthcare stocks with a strong pulse. Yahoo Finance
07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
02:56AM  [video]Celgene Slips on Post-Earnings Analyst Downgrade TheStreet.com
Oct-31-19 04:16PM  This Drug Giant Is Breaking Out But A Key Blockbuster Could Be In Trouble Investor's Business Daily
01:12PM  Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise Zacks
11:37AM  Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates Zacks
09:25AM  Celgene (CELG) Q3 Earnings and Revenues Top Estimates Zacks
07:43AM  Celgene tops earnings estimates in latest quarter MarketWatch
07:30AM  Celgene Reports Third Quarter 2019 Operating and Financial Results Business Wire
Oct-30-19 11:12AM  Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D Zacks
Oct-29-19 12:01PM  Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings? Zacks
Oct-28-19 05:10PM  11 Stocks With The Highest Gross Margins Benzinga
12:04PM  Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings Zacks
Oct-25-19 11:25AM  Amgen (AMGN) to Report Q3 Earnings: What's in the Cards? Zacks
10:10AM  Why the Earnings Surprise Streak Could Continue for Celgene (CELG) Zacks
Oct-24-19 05:52PM  Can This New Stock Chart Technology Help You Hold Top Growth Stocks Longer? Investor's Business Daily
10:32AM  Celgene (CELG) Earnings Expected to Grow: Should You Buy? Zacks
08:40AM  Factors Setting the Tone for Celgene (CELG) Q3 Earnings Zacks
Oct-19-19 07:30AM  A Giant Fund Sold Disney, Celgene Stock, Bought Morgan Stanley and Oracle Barrons.com
Oct-18-19 07:04AM  Alexion to Buy Achillion for $930M, Strengthen PNH Franchise Zacks
Oct-17-19 11:24AM  Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks
10:41AM  4 Biotech Stocks That Are Set to Rally, Analyst Says Barrons.com
10:33AM  Celgene (CELG) Earnings Expected to Grow: Should You Buy? Zacks
Oct-16-19 12:16PM  Editas Inks Deal for Gene Editing Neurological Disease Drugs Zacks
06:00AM  Celgene and the Multiple Sclerosis Association of America Take the MS MindShift Initiative and Brain Bulb Hot Air Balloon to the Sky at Owl-O-Ween Festival to Educate on Multiple Sclerosis and Brain Health Business Wire
Oct-15-19 12:21PM  AbbVie, Bristol-Myers Squibb Getting the Most From Workers GuruFocus.com
Oct-11-19 09:45AM  Geron Starts Enrollment in Phase III MDS Study on Imetelstat Zacks
Oct-10-19 04:08PM  6 Stocks Trading Below Peter Lynch Value GuruFocus.com
Oct-08-19 09:18AM  Why Alexion is a Hot Takeover Target in the Biotech Sector Zacks
Oct-04-19 09:30AM  3 Drug Stocks Poised for Gains After Cancer Conference Investopedia
Oct-03-19 04:49PM  Here is Hedge Funds 17th Most Popular Stock Pick Insider Monkey
03:02PM  3 Cancer-Fighting Drug Stocks to Buy Right Now InvestorPlace
Oct-02-19 11:36AM  Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study Zacks
Oct-01-19 10:36AM  Geron's Imetelstat Gets Fast Track Status for Myelofibrosis Zacks
Sep-30-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
Sep-27-19 10:47AM  Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance Zacks
Sep-25-19 10:36AM  Adding Biotech ETFs to Your Portfolio Investopedia
Sep-23-19 05:50PM  Celgene (CELG) Gains As Market Dips: What You Should Know Zacks
Sep-20-19 05:48PM  3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices GuruFocus.com
11:04AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
08:31AM  3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks
07:30AM  Celgene Corporation Names Second Round of Celgene Cancer Care Links Program Grant Recipients Business Wire
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks
Sep-17-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
10:39AM  Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks
10:14AM  The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial Zacks
Sep-16-19 02:25PM  Top Stock Reports for Celgene, Sinopec & HSBC Zacks
08:48AM  Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study Zacks
Sep-13-19 10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
09:18AM  Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says Barrons.com
07:40AM  The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans Benzinga
Sep-12-19 04:30PM  Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints Business Wire
09:41AM  J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients Zacks
Sep-11-19 05:50PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
Sep-10-19 06:00PM  FDA Grants Orphan Drug Status to Acceleron's PAH Candidate Zacks
Sep-09-19 07:30AM  Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Business Wire
Sep-08-19 09:00AM  Better Buy: Amgen vs. Celgene Motley Fool
Sep-07-19 12:30PM  Is Bristol-Myers Squibb a Buy? Motley Fool
Sep-06-19 03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
08:39AM  Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer Zacks
05:21AM  China biotech group shares slide over accusation of sales inflation Financial Times
Sep-05-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
REICIN ALISEPRES., GLOBAL CLINICAL DEV.Nov 01Option Exercise0.0011,903011,903Nov 04 04:05 PM
AHMED NADIMPRES., GLOBAL HEM. AND ONC.Oct 31Option Exercise0.003,281015,915Nov 04 04:05 PM
VESSEY RUPERTSEE REMARKSOct 31Option Exercise0.005,369016,822Nov 04 04:05 PM
Curran TerrieSEE REMARKSOct 31Option Exercise0.003,28105,436Nov 04 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELOct 31Option Exercise0.003,12507,309Nov 04 04:05 PM
COX CARRIE SMITHDirectorOct 29Option Exercise25.8912,500323,62542,580Nov 06 04:05 PM
Curran TerrieSEE REMARKSSep 18Option Exercise58.334,500262,48513,493Sep 19 04:05 PM
Curran TerrieSEE REMARKSSep 18Sale98.2711,3381,114,1442,155Sep 19 04:05 PM
Elkins David VEVP, CHIEF FINANCIAL OFFICERAug 01Option Exercise0.0024,947024,947Aug 05 04:00 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037502,209Jun 17 04:00 PM
BARKER RICHARD WDirectorJun 15Option Exercise0.001,125013,673Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441041,861Jun 17 04:00 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375062,884Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037502,409Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0030001,834Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300039,420Jun 17 04:00 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300062,509Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
Haller Julia ADirectorJun 14Option Exercise0.0030002,034Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0048401,534Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 13Option Exercise0.00484039,120Jun 17 04:00 PM
Friedman Michael ADirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
MARIO ERNESTDirectorJun 13Option Exercise0.00484062,209Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
Haller Julia ADirectorJun 13Option Exercise0.0048401,734Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 03Option Exercise22.4724,666554,24524,666Jun 05 04:05 PM
Curran TerrieSEE REMARKSMay 02Option Exercise0.001,56309,483May 06 04:05 PM
VESSEY RUPERTSEE REMARKSMay 02Option Exercise0.006,731013,984May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 02Option Exercise0.0015,6080227,886May 06 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELMay 02Option Exercise0.001,56304,674May 06 04:05 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYMay 02Option Exercise0.001,563013,124May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM